Shopping Cart 0
Cart Subtotal
USD 0

Oncology Biosimilars Market Global Report 2020-30

Bundle Purchase

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 4000

Access to Printed Report; No Soft Copy
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : Printed Publication/ Book by Post

Hard Copy License
USD 4000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 6000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

CD-Rom
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 8000

Details

The oncology biosimilars market consists of sales of medicine and drug related products for cancer treatment. Biosimilars are pharmaceuticals which are manufactured using cell lines and are exclusive to the manufacturer. The manufacturing of these cell line processes is a complex and time-consuming process.
 
The global oncology biosimilars market was worth USD 2990.34 million in 2019. It is expected to grow at a compound annual growth rate (CAGR) of 33.17% and reach USD 9404.54 million by 2023.
 
The oncology biosimilars market covered in this report is segmented by drug type into monoclonal antibody, immunomodulators, hematopoietic agents, granulocyte colony-stimulating factor (G-CSF). It is also segmented by cancer type into breast cancer, colorectal cancer, blood cancer, neutropenia cancer, non-small cell lung cancer, others and by distribution type into hospital pharmacy, retail pharmacy and online pharmacy.
 
The expiration of patent of biologics used for the treatment of cancer is driving the production of new oncology biosimilars. Biologics can be patented for a limited period and the expiration of patents for biologics allows the development of new biosimilars. Biologics are targeted drugs synthesized from living organisms which induces the immune system to attack cancer cells. Biosimilars are similar to biologics but are not identical and offers the same effectiveness as biologics at a reduced cost. According to the Center for Biosimilars, patents on nearly 20 oncology biologics will expire by 2023, leading to the development of new biosimilars in cancer care. The increased number of patent expiry is expected to boost the demand for the production of new oncology biosimilars, thus, driving the market growth for oncology biosimilars.
 
The lack of awareness on biosimilars among primary care physicians (PCPs) and specialist limits the growth of the oncology biosimilars market. Biosimilars are manufactured from cell lines and offer the same effectiveness as biologics. However, lack of detailed awareness on the biosimilars amongst the prescribers reduces the prescriptions of biosimilars affecting the biosimilar market. For instance, as reported in 2018 by the Health Research Institute of PricewaterhouseCoopers, out of 442 clinicians surveyed 55% of clinicians were unfamiliar with biosimilars and 35% were reluctant to prescribe them due to concerns included safety of the follow-on biologic. Thus, the lack of awareness about biosimilars among primary care physicians (PCPs) and specialists restricts the growth of the oncology biosimilars market.
 
The pharmaceutical companies are increasingly investing in research and development to produce new oncology biosimilars. The companies are exploiting growth potential of rising biosimilar market by investing in their research and development (R&D) processes to support the research and production process of new biosimilars. For instance, in the fiscal year 2017, Aurobindo Pharma spent USD 80 million to support the research for the biosimilars including oncology biosimilars. Also, in 2019, Biocon, India's largest biotechnology company invested to acquire some assets of Pfizer Healthcare to set up R&D facility to boost biosimilar development.
 
Major players in the market are Biocoin, Celltrion Inc., Dr. Reddy's Laboratories Ltd., Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Pfizer Inc., Apotex Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH and BIOCAD.
READ MORE

Table Of Content

Scope

1. Executive Summary

2. Oncology Biosimilars Market Characteristics

3. Oncology Biosimilars Market Size And Growth

3.1. Global Oncology Biosimilars Historic Market, 2015-2019, USD Billion

3.1.1. Drivers Of The Market

3.1.2. Restraints On The Market

3.2. Global Oncology Biosimilars Forecast Market, 2019-2023F, 2025F, 2030F, USD Billion

3.2.1. Drivers Of The Market

3.2.2. Restraints On the Market

4. Oncology Biosimilars Market Segmentation

4.1. Global Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Monoclonal Antibody

Immunomodulators

Hematopoietic Agents

Granulocyte Colony-Stimulating Factor (G-CSF)

4.2. Global Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Breast Cancer

Colorectal Cancer

Blood Cancer

Neutropenia Cancer

Non-Small Cell Lung Cancer

Others

4.3. Global Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

5. Oncology Biosimilars Market Regional And Country Analysis

5.1. Global Oncology Biosimilars Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

5.2. Global Oncology Biosimilars Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

6. Asia-Pacific Oncology Biosimilars Market

6.1. Asia-Pacific Oncology Biosimilars Market Overview

6.2. Asia-Pacific Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

7. China Oncology Biosimilars Market

7.1. China Oncology Biosimilars Market Overview

7.2. China Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F,USD Billion

8. India Oncology Biosimilars Market

8.1. India Oncology Biosimilars Market Overview

8.2. India Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

9. Japan Oncology Biosimilars Market

9.1. Japan Oncology Biosimilars Market Overview

9.2. Japan Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

10. Australia Oncology Biosimilars Market

10.1. Australia Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

11. Indonesia Oncology Biosimilars Market

11.1. Indonesia Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

12. South Korea Oncology Biosimilars Market

12.1. South Korea Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

13. Western Europe Oncology Biosimilars Market

13.1. Western Europe Oncology Biosimilars Market Overview

13.2. Western Europe Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

14. UK Oncology Biosimilars Market

14.1. UK Oncology Biosimilars Market Overview

14.2. UK Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

15. Germany Oncology Biosimilars Market

15.1. Germany Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

16. France Oncology Biosimilars Market

16.3. France Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

17. Eastern Europe Oncology Biosimilars Market

17.1. Eastern Europe Oncology Biosimilars Market Overview

17.2. Eastern Europe Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

18. Russia Oncology Biosimilars Market

18.1. Russia Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

19. North America Oncology Biosimilars Market

19.1. North America Oncology Biosimilars Market Overview

19.2. North America Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

20. USA Oncology Biosimilars Market

20.1. USA Oncology Biosimilars Market Overview

20.2. USA Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

21. South America Oncology Biosimilars Market

21.1. South America Oncology Biosimilars Market Overview

21.2. South America Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

22. Brazil Oncology Biosimilars Market

22.1. Brazil Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

23. Middle East Oncology Biosimilars Market

23.1. Middle East Oncology Biosimilars Market Overview

23.2. Middle East Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

24. Africa Oncology Biosimilars Market

24.1. Africa Oncology Biosimilars Market Overview

24.2. Africa Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

25. Oncology Biosimilars Market Competitive Landscape And Company Profiles

25.1. Oncology Biosimilars Market Competitive Landscape

25.2. Oncology Biosimilars Market Company Profiles

25.2.1. Biocoin

25.2.1.1. Overview

25.2.1.2. Products and Services

25.2.1.3. Strategy

25.2.1.4. Financial Performance

25.2.2. Celltrion Inc.

25.2.2.1. Overview

25.2.2.2. Products and Services

25.2.2.3. Strategy

25.2.2.4. Financial Performance

25.2.3. Dr. Reddy's Laboratories Ltd.

25.2.3.1. Overview

25.2.3.2. Products and Services

25.2.3.3. Strategy

25.2.3.4. Financial Performance

25.2.4. Intas Pharmaceuticals Ltd.

25.2.4.1. Overview

25.2.4.2. Products and Services

25.2.4.3. Strategy

25.2.4.4. Financial Performance

25.2.5. STADA Arzneimittel AG

25.2.5.1. Overview

25.2.5.2. Products and Services

25.2.5.3. Strategy

25.2.5.4. Financial Performance

26. Key Mergers And Acquisitions In The Oncology Biosimilars Market

27. Oncology Biosimilars Market Trends And Strategies

28. Oncology Biosimilars Market Future Outlook and Potential Analysis

29. Appendix

29.1. Abbreviations

29.2. Currencies

29.3. Research Inquiries

29.4. The Business Research Company

29.5. Copyright And Disclaimer

 


List Of Figure

Figure 1: Global Historic Market Growth, 2015-2019, USD Billion

Figure 2: Global Forecast Market Growth, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 3: Global Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 4: Global Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 5: Global Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 6: Global Oncology Biosimilars Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 7: Global Oncology Biosimilars Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 8: Asia-Pacific, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 9: China, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 10: India, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 11: Japan, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 12: Australia, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 13: Indonesia, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 14: South Korea, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 15: Western Europe, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 16: UK, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 17: Germany, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 18: France, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 19: Eastern Europe, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 20: Russia, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 21: North America, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 22: USA, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 23: South America, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 24: Brazil, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 25: Middle East, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 26: Africa, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 27: Biocoin Financial Performance

Figure 28: Celltrion Inc. Financial Performance

Figure 29: Dr. Reddy's Laboratories Ltd. Financial Performance

Figure 30: Intas Pharmaceuticals Ltd. Financial Performance

Figure 31: STADA Arzneimittel AG Financial Performance


List Of Table

Table 1: Global Historic Market Growth, 2015-2019, USD Billion

Table 2: Global Forecast Market Growth, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 3: Global Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 4: Global Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 5: Global Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 6: Global Oncology Biosimilars Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 7: Global Oncology Biosimilars Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 8: Asia-Pacific, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 9: China, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 10: India, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 11: Japan, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 12: Australia, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 13: Indonesia, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 14: South Korea, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 15: Western Europe, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 16: UK, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 17: Germany, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 18: France, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 19: Eastern Europe, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 20: Russia, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 21: North America, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 22: USA, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 23: South America, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 24: Brazil, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 25: Middle East, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 26: Africa, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 27: Biocoin Financial Performance

Table 28: Celltrion Inc. Financial Performance

Table 29: Dr. Reddy's Laboratories Ltd. Financial Performance

Table 30: Intas Pharmaceuticals Ltd. Financial Performance

Table 31: STADA Arzneimittel AG Financial Performance

Licence Rights

  • Single User License (for access by one person)
  • Site License (for access of one office location of a company)
  • Corporate License (allow access by all staff of the company)

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

1) By Drug Type: Monoclonal Antibody; Immunomodulators; Hematopoietic Agents; Granulocyte Colony-Stimulating Factor (G-CSF); 2) By Cancer Type: Breast Cancer; Colorectal Cancer; Blood Cancer; Neutropenia Cancer; Non-Small Cell Lung Cancer; Others; 3) By Distribution Type: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy


Companies

Biocoin; Celltrion Inc.; Dr. Reddy's Laboratories Ltd.; Intas Pharmaceuticals Ltd.; STADA Arzneimittel AG; Pfizer Inc.; Apotex Inc.; Teva Pharmaceutical Industries Ltd.; Sandoz International GmbH; BIOCAD; Amgen; Hospira; F Hoffmann-La Roche; Baxter; Sanofi; Mylan; F Hoffmann-La Roche

Company Profile

Company Profile Title

The oncology biosimilars market consists of sales of medicine and drug related products for cancer treatment. Biosimilars are pharmaceuticals which are manufactured using cell lines and are exclusive to the manufacturer. The manufacturing of these cell line processes is a complex and time-consuming process.
 
The global oncology biosimilars market was worth USD 2990.34 million in 2019. It is expected to grow at a compound annual growth rate (CAGR) of 33.17% and reach USD 9404.54 million by 2023.
 
The oncology biosimilars market covered in this report is segmented by drug type into monoclonal antibody, immunomodulators, hematopoietic agents, granulocyte colony-stimulating factor (G-CSF). It is also segmented by cancer type into breast cancer, colorectal cancer, blood cancer, neutropenia cancer, non-small cell lung cancer, others and by distribution type into hospital pharmacy, retail pharmacy and online pharmacy.
 
The expiration of patent of biologics used for the treatment of cancer is driving the production of new oncology biosimilars. Biologics can be patented for a limited period and the expiration of patents for biologics allows the development of new biosimilars. Biologics are targeted drugs synthesized from living organisms which induces the immune system to attack cancer cells. Biosimilars are similar to biologics but are not identical and offers the same effectiveness as biologics at a reduced cost. According to the Center for Biosimilars, patents on nearly 20 oncology biologics will expire by 2023, leading to the development of new biosimilars in cancer care. The increased number of patent expiry is expected to boost the demand for the production of new oncology biosimilars, thus, driving the market growth for oncology biosimilars.
 
The lack of awareness on biosimilars among primary care physicians (PCPs) and specialist limits the growth of the oncology biosimilars market. Biosimilars are manufactured from cell lines and offer the same effectiveness as biologics. However, lack of detailed awareness on the biosimilars amongst the prescribers reduces the prescriptions of biosimilars affecting the biosimilar market. For instance, as reported in 2018 by the Health Research Institute of PricewaterhouseCoopers, out of 442 clinicians surveyed 55% of clinicians were unfamiliar with biosimilars and 35% were reluctant to prescribe them due to concerns included safety of the follow-on biologic. Thus, the lack of awareness about biosimilars among primary care physicians (PCPs) and specialists restricts the growth of the oncology biosimilars market.
 
The pharmaceutical companies are increasingly investing in research and development to produce new oncology biosimilars. The companies are exploiting growth potential of rising biosimilar market by investing in their research and development (R&D) processes to support the research and production process of new biosimilars. For instance, in the fiscal year 2017, Aurobindo Pharma spent USD 80 million to support the research for the biosimilars including oncology biosimilars. Also, in 2019, Biocon, India's largest biotechnology company invested to acquire some assets of Pfizer Healthcare to set up R&D facility to boost biosimilar development.
 
Major players in the market are Biocoin, Celltrion Inc., Dr. Reddy's Laboratories Ltd., Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Pfizer Inc., Apotex Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH and BIOCAD.
READ MORE

Scope

1. Executive Summary

2. Oncology Biosimilars Market Characteristics

3. Oncology Biosimilars Market Size And Growth

3.1. Global Oncology Biosimilars Historic Market, 2015-2019, USD Billion

3.1.1. Drivers Of The Market

3.1.2. Restraints On The Market

3.2. Global Oncology Biosimilars Forecast Market, 2019-2023F, 2025F, 2030F, USD Billion

3.2.1. Drivers Of The Market

3.2.2. Restraints On the Market

4. Oncology Biosimilars Market Segmentation

4.1. Global Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Monoclonal Antibody

Immunomodulators

Hematopoietic Agents

Granulocyte Colony-Stimulating Factor (G-CSF)

4.2. Global Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Breast Cancer

Colorectal Cancer

Blood Cancer

Neutropenia Cancer

Non-Small Cell Lung Cancer

Others

4.3. Global Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

5. Oncology Biosimilars Market Regional And Country Analysis

5.1. Global Oncology Biosimilars Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

5.2. Global Oncology Biosimilars Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

6. Asia-Pacific Oncology Biosimilars Market

6.1. Asia-Pacific Oncology Biosimilars Market Overview

6.2. Asia-Pacific Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

7. China Oncology Biosimilars Market

7.1. China Oncology Biosimilars Market Overview

7.2. China Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F,USD Billion

8. India Oncology Biosimilars Market

8.1. India Oncology Biosimilars Market Overview

8.2. India Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

9. Japan Oncology Biosimilars Market

9.1. Japan Oncology Biosimilars Market Overview

9.2. Japan Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

10. Australia Oncology Biosimilars Market

10.1. Australia Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

11. Indonesia Oncology Biosimilars Market

11.1. Indonesia Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

12. South Korea Oncology Biosimilars Market

12.1. South Korea Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

13. Western Europe Oncology Biosimilars Market

13.1. Western Europe Oncology Biosimilars Market Overview

13.2. Western Europe Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

14. UK Oncology Biosimilars Market

14.1. UK Oncology Biosimilars Market Overview

14.2. UK Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

15. Germany Oncology Biosimilars Market

15.1. Germany Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

16. France Oncology Biosimilars Market

16.3. France Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

17. Eastern Europe Oncology Biosimilars Market

17.1. Eastern Europe Oncology Biosimilars Market Overview

17.2. Eastern Europe Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

18. Russia Oncology Biosimilars Market

18.1. Russia Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

19. North America Oncology Biosimilars Market

19.1. North America Oncology Biosimilars Market Overview

19.2. North America Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

20. USA Oncology Biosimilars Market

20.1. USA Oncology Biosimilars Market Overview

20.2. USA Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

21. South America Oncology Biosimilars Market

21.1. South America Oncology Biosimilars Market Overview

21.2. South America Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

22. Brazil Oncology Biosimilars Market

22.1. Brazil Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

23. Middle East Oncology Biosimilars Market

23.1. Middle East Oncology Biosimilars Market Overview

23.2. Middle East Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

24. Africa Oncology Biosimilars Market

24.1. Africa Oncology Biosimilars Market Overview

24.2. Africa Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

25. Oncology Biosimilars Market Competitive Landscape And Company Profiles

25.1. Oncology Biosimilars Market Competitive Landscape

25.2. Oncology Biosimilars Market Company Profiles

25.2.1. Biocoin

25.2.1.1. Overview

25.2.1.2. Products and Services

25.2.1.3. Strategy

25.2.1.4. Financial Performance

25.2.2. Celltrion Inc.

25.2.2.1. Overview

25.2.2.2. Products and Services

25.2.2.3. Strategy

25.2.2.4. Financial Performance

25.2.3. Dr. Reddy's Laboratories Ltd.

25.2.3.1. Overview

25.2.3.2. Products and Services

25.2.3.3. Strategy

25.2.3.4. Financial Performance

25.2.4. Intas Pharmaceuticals Ltd.

25.2.4.1. Overview

25.2.4.2. Products and Services

25.2.4.3. Strategy

25.2.4.4. Financial Performance

25.2.5. STADA Arzneimittel AG

25.2.5.1. Overview

25.2.5.2. Products and Services

25.2.5.3. Strategy

25.2.5.4. Financial Performance

26. Key Mergers And Acquisitions In The Oncology Biosimilars Market

27. Oncology Biosimilars Market Trends And Strategies

28. Oncology Biosimilars Market Future Outlook and Potential Analysis

29. Appendix

29.1. Abbreviations

29.2. Currencies

29.3. Research Inquiries

29.4. The Business Research Company

29.5. Copyright And Disclaimer

 


List Of Figure

Figure 1: Global Historic Market Growth, 2015-2019, USD Billion

Figure 2: Global Forecast Market Growth, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 3: Global Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 4: Global Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 5: Global Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 6: Global Oncology Biosimilars Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 7: Global Oncology Biosimilars Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 8: Asia-Pacific, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 9: China, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 10: India, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 11: Japan, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 12: Australia, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 13: Indonesia, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 14: South Korea, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 15: Western Europe, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 16: UK, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 17: Germany, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 18: France, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 19: Eastern Europe, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 20: Russia, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 21: North America, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 22: USA, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 23: South America, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 24: Brazil, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 25: Middle East, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 26: Africa, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 27: Biocoin Financial Performance

Figure 28: Celltrion Inc. Financial Performance

Figure 29: Dr. Reddy's Laboratories Ltd. Financial Performance

Figure 30: Intas Pharmaceuticals Ltd. Financial Performance

Figure 31: STADA Arzneimittel AG Financial Performance


List Of Table

Table 1: Global Historic Market Growth, 2015-2019, USD Billion

Table 2: Global Forecast Market Growth, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 3: Global Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 4: Global Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 5: Global Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 6: Global Oncology Biosimilars Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 7: Global Oncology Biosimilars Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 8: Asia-Pacific, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 9: China, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 10: India, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 11: Japan, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 12: Australia, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 13: Indonesia, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 14: South Korea, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 15: Western Europe, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 16: UK, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 17: Germany, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 18: France, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 19: Eastern Europe, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 20: Russia, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 21: North America, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 22: USA, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 23: South America, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 24: Brazil, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 25: Middle East, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 26: Africa, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 27: Biocoin Financial Performance

Table 28: Celltrion Inc. Financial Performance

Table 29: Dr. Reddy's Laboratories Ltd. Financial Performance

Table 30: Intas Pharmaceuticals Ltd. Financial Performance

Table 31: STADA Arzneimittel AG Financial Performance

  • Single User License (for access by one person)
  • Site License (for access of one office location of a company)
  • Corporate License (allow access by all staff of the company)
To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

1) By Drug Type: Monoclonal Antibody; Immunomodulators; Hematopoietic Agents; Granulocyte Colony-Stimulating Factor (G-CSF); 2) By Cancer Type: Breast Cancer; Colorectal Cancer; Blood Cancer; Neutropenia Cancer; Non-Small Cell Lung Cancer; Others; 3) By Distribution Type: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy


Companies

Biocoin; Celltrion Inc.; Dr. Reddy's Laboratories Ltd.; Intas Pharmaceuticals Ltd.; STADA Arzneimittel AG; Pfizer Inc.; Apotex Inc.; Teva Pharmaceutical Industries Ltd.; Sandoz International GmbH; BIOCAD; Amgen; Hospira; F Hoffmann-La Roche; Baxter; Sanofi; Mylan; F Hoffmann-La Roche